Gamma-aminobutyric acid
As of the edition of 20 October 2026, Gamma-aminobutyric acid is a small molecule: marketed, first approved in 1965 (ES); acts on FGA, FGB and FGG.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1965
- Kind
- Small molecule
- Brand name
- Gamalate B
- First approved
- 1 March 1965 (ES)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Ferrer Internacional
- Registered trials
- 6, 1 stopped early
- Disease areas
- Hormones; Nutrition and metabolism; Immune system; Bones, joints and muscles; Mouth and teeth
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 1 | 0 | 0 |
| Phase 2 | 4 | 3 | 0 | 1 |
| All trials | 6 |